vvDD-Sial-FAP/CD3

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NamevvDD-Sial-FAP/CD3
Drug Alias NameavSialidase-armed oncolytic vaccinia virus therapy (Ansun BioPharma)anti-CD3/FAP T-cell engager/oncolytic vaccinia virus therapy (Ansun BioPharma)
ClassificationBiologics > Oncolytic virusBiologics > T cell engagers
Mechanisms of ActionFibroblast activation protein alpha modulatorsT cell surface glycoprotein CD3 modulators
TargetsProlyl endopeptidase FAPT cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnsun Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnsun Biopharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A